ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, wh… Read more
ORUM (475830) - Total Liabilities
Latest total liabilities as of March 2025: ₩29.73 Billion KRW
Based on the latest financial reports, ORUM (475830) has total liabilities worth ₩29.73 Billion KRW as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ORUM - Total Liabilities Trend (2022–2024)
This chart illustrates how ORUM's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ORUM Competitors by Total Liabilities
The table below lists competitors of ORUM ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Next Mediaworks Limited
NSE:NEXTMEDIA
|
India | ₹369.00 Million |
|
Northgold AB
ST:NG
|
Sweden | Skr3.21 Million |
|
Omkar Speciality Chemicals Limited
NSE:OMKARCHEM
|
India | ₹2.43 Billion |
|
Sileon AB
ST:SILEON
|
Sweden | Skr42.60 Million |
|
Trucept Inc
PINK:TREP
|
USA | $7.45 Million |
|
DriveItAway Inc
PINK:DWAY
|
USA | $9.18 Million |
|
Totalindo Eka Persada Tbk PT
JK:TOPS
|
Indonesia | Rp1.21 Trillion |
|
Rapid Nutrition PLC
PINK:RPNRF
|
USA | $475.72K |
Liability Composition Analysis (2022–2024)
This chart breaks down ORUM's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.31 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ORUM's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ORUM (2022–2024)
The table below shows the annual total liabilities of ORUM from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩32.07 Billion | -85.29% |
| 2023-12-31 | ₩217.96 Billion | +46.54% |
| 2022-12-31 | ₩148.74 Billion | -- |